Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain
| Autor: | Letícia Nishi, Idessania Nazareth Costa, Francini Martini Mantelo, Ana Lúcia Falavigna-Guilherme, Amanda Hinobu de Souza, A. M. Souza-Kaneshima, F. F. Evangelista, Priscilla de Laet Santana, Lucimara Fátima Beletini |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Necrosis 030231 tropical medicine Antiprotozoal Agents Biology Parasite load Mice 03 medical and health sciences 0302 clinical medicine Sulfadiazine In vivo medicine Animals Rosuvastatin Rosuvastatin Calcium Brain medicine.disease Toxoplasmosis Disease Models Animal Chronic infection Toxoplasmosis Animal 030104 developmental biology Infectious Diseases Pyrimethamine Chronic Disease Female Animal Science and Zoology Parasitology Hydroxymethylglutaryl-CoA Reductase Inhibitors medicine.symptom Toxoplasma Research Article medicine.drug |
| Zdroj: | Parasitology |
| ISSN: | 1469-8161 0031-1820 |
| Popis: | This study evaluated the effects of rosuvastatin in vivo on toxoplasmosis chronic infection. Thirty-five Swiss mice were orally infected (ME-49 strain). After 50 days, the mice were separated into five groups: GI – non-infected, GII – infected, GIII – infected and treated with pyrimethamine and sulfadiazine (12.5 + 50 mg kg−1 body weight day−1), GIV and GV – infected and treated with rosuvastatin 10 and 40 mg kg−1 body weight day−1, respectively. After 21 days, we collected blood, liver, lungs, femoral biceps and brain were removed for Toxoplasma gondii DNA quantification by qPCR and histopathological analysis. GIV and GV did not present premature death or clinical changes, and the hepatic enzyme levels were lower compared to GI. Toxoplasma gondii DNA was detected mainly in brain and muscle, but the parasite load was significantly lower in GV compared to GII brains (P < 0.05). Histopathological changes were observed in brains, with T. gondii cysts as well as an inflammatory condition, including necrosis areas in GII and GIII. These data confirm active infection with tissue injury. This inflammatory condition was attenuated in the groups treated with rosuvastatin, especially R40 (GV). Our findings demonstrated the in vivo action of rosuvastatin in reducing cerebral parasitic load and indicate that this drug may interfere in chronic toxoplasmosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|